Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
pancreatic ductal adenocarcinoma
perineural invasion
risk stratification
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Apr 2022
23 Apr 2022
Historique:
received:
14
03
2022
revised:
13
04
2022
accepted:
20
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
(1) Background: Perineural invasion (PNI) is a common characteristic of pancreatic ductal adenocarcinoma (PDAC) and is present in most resection margins. We hypothesized that curative pancreatic tumor resection with long-term survival could only be achieved in PNI-negative patients. (2) Material and Methods: A retrospective investigation of PDAC patients who underwent curative-intended surgery during the period 2008 to 2019 was performed at our institution. (3) Results: We identified 571 of 660 (86.5%) resected patients with well-annotated reports and complete datasets. Of those, 531 patients (93%) exhibited tumors with perineural invasion (Pn1), while 40 (7%) were negative for PNI (Pn0). The majority of patients in the Pn1 group presented advanced tumor stage and positive lymph node infiltration. Patients in the Pn0 group showed an improved disease-free and long-term survival compared to the Pn1 group (p < 0.001). Subgroup analysis of all R0-resected patients indicated improved long-term survival and disease-free survival of R0 Pn0 patients when compared to R0 Pn1 patients (p < 0.001). (4) Conclusion: Our study confirmed that Pn0 improves the long-term survival of PDAC-resected cancer patients. Furthermore, PNI significantly challenges the long-term survival of formally curative (R0) resected patients. We provide new insights into the dynamics of PNI in pancreatic cancer patients which are needed to define subgroups of patients for risk stratification and multimodal treatment strategies.
Identifiants
pubmed: 35566494
pii: jcm11092367
doi: 10.3390/jcm11092367
pmc: PMC9103867
pii:
doi:
Types de publication
Journal Article
Langues
eng
Commentaires et corrections
Type : ErratumIn
Références
Radiology. 2018 May;287(2):374-390
pubmed: 29668413
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
JAMA Oncol. 2021 Mar 1;7(3):421-427
pubmed: 33475684
Ann Surg. 2017 Jan;265(1):185-191
pubmed: 27163957
Pancreatology. 2018 Jan;18(1):2-11
pubmed: 29191513
Ann Surg. 2019 Mar;269(3):520-529
pubmed: 29068800
Cancers (Basel). 2020 Apr 30;12(5):
pubmed: 32366019
JAMA Oncol. 2018 Jul 1;4(7):963-969
pubmed: 29800971
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Ann Surg Oncol. 2018 Apr;25(4):1043-1051
pubmed: 29302820
J Surg Oncol. 2017 Nov;116(6):658-664
pubmed: 28628722
Ann Surg. 2020 Oct 19;:
pubmed: 33086324
Cancer Sci. 2012 Oct;103(10):1756-63
pubmed: 22716017
Ann Surg Oncol. 2020 Apr;27(4):1191-1200
pubmed: 31802297
JAMA. 2010 Sep 8;304(10):1073-81
pubmed: 20823433
Am J Surg Pathol. 2012 Mar;36(3):409-17
pubmed: 22301497
J Surg Oncol. 2019 Sep;120(3):483-493
pubmed: 31197842
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457
pubmed: 33845462
Ann Surg. 2018 May;267(5):936-945
pubmed: 28338509
Ann Surg. 2014 Nov;260(5):900-7; discussion 907-8
pubmed: 25379860
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1187-95
pubmed: 26362048
Cancer. 2010 Nov 15;116(22):5336-9
pubmed: 20665503
Ann Surg. 2015 Jan;261(1):12-7
pubmed: 25599322
Front Oncol. 2020 Jan 31;10:41
pubmed: 32083002
Pancreas. 2007 Oct;35(3):218-23
pubmed: 17895841
J Clin Oncol. 2016 Jul 20;34(21):2541-56
pubmed: 27247221
Cancer Res. 2014 Mar 1;74(5):1529-40
pubmed: 24448236
Cancer Res. 2014 Mar 15;74(6):1718-27
pubmed: 24448244
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Ann Surg Oncol. 2016 Jun;23(6):2010-8
pubmed: 26832882
Diagnostics (Basel). 2021 Nov 22;11(11):
pubmed: 34829513
Mol Cancer Ther. 2009 Jun;8(6):1494-504
pubmed: 19509238
Cancers (Basel). 2019 Jun 26;11(7):
pubmed: 31248001
Cancer Res. 2012 Nov 15;72(22):5733-43
pubmed: 22971345
Anticancer Res. 2019 Oct;39(10):5781-5787
pubmed: 31570482
Arch Surg. 2012 Aug;147(8):753-60
pubmed: 22911074
Surg Oncol. 2017 Mar;26(1):105-115
pubmed: 28317579
Br J Surg. 2019 Jul;106(8):1055-1065
pubmed: 30883699